Latest & greatest articles for latanoprost

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on latanoprost or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on latanoprost and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for latanoprost

1. Efficacy and safety of 0.0015% tafluprost versus 0.005% latanoprost in primary open angle glaucoma, ocular hypertension: a Meta-analysis. (Full text)

Efficacy and safety of 0.0015% tafluprost versus 0.005% latanoprost in primary open angle glaucoma, ocular hypertension: a Meta-analysis. To evaluate the intraocular pressure (IOP)-lowering efficacy and safety of tafluprost 0.0015% eye drops [benzalkonium chloride (BAK) 0.1 mg/mL] compared with that of latanoprost 0.005% eye drops (BAK 0.2 mg/mL) for primary open angle glaucoma (POAG) and ocular hypertension (OHT).All the randomized controlled trials (RCTs) about treating POAG and OHT comparing (...) tafluprost and latanoprost were collected by searching PubMed, Embase, Cochrane Library, CNKI and VIP. The outcomes of interest to evaluate the clinical efficacy and adverse effects included IOP and patient-related drop discomfort.Five RCTs involving 888 glaucoma patients were included. The results showed that, 1) at the end of the study, no statistically significant differences were observed in IOP reduction [standard mean difference (SMD) =0.48, 95%CI 0.07 to 0.88, P=0.085] between tafluprost

2020 International journal of ophthalmology PubMed abstract

2. The efficacy of the fixed combination of latanoprost and timolol versus other fixed combinations for primary open-angle glaucoma and ocular hypertension: A systematic review and meta-analysis. (Full text)

The efficacy of the fixed combination of latanoprost and timolol versus other fixed combinations for primary open-angle glaucoma and ocular hypertension: A systematic review and meta-analysis. Fixed-combination (FC) therapy is used in primary open-angle glaucoma (POAG) and ocular hypertension (OHT) patients who require more than one medication to reach their target intraocular pressure (IOP). Currently, there are several FC therapies available for the treatment of glaucoma. The FC (...) of latanoprost/timolol (LTFC) is a commonly used FC. Here, we conducted systematic review to compare the IOP-lowering effects of LTFC with other FCs for patients with POAG and OHT.We searched PubMed, EMBASE, the Cochrane Library, and Web of Science for randomized-controlled clinical trials and cross-over studies. The outcomes were mean IOP and IOP fluctuation after one month of treatment. Meta-analysis was carried out using RevMan (version 5.1) software. After conducting meta-analyses, we rated the quality

2020 PloS one PubMed abstract

3. Latanoprost + timolol (Fixapost) Reduction of intraocular pressure (IOP) in patients with open angle glaucoma and ocular hypertension who are insufficiently responsive to topical beta-blockers or prostaglandin analogues.

Latanoprost + timolol (Fixapost) Reduction of intraocular pressure (IOP) in patients with open angle glaucoma and ocular hypertension who are insufficiently responsive to topical beta-blockers or prostaglandin analogues. Published 13 May 2019 Product update SMC2159 latanoprost 50 micrograms/mL plus timolol 5mg/mL preservative free eye drops (Fixapost®) Thea Pharmaceuticals Limited 5 April 2019 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises (...) NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows: ADVICE: following an abbreviated submission latanoprost plus timolol (Fixapost®) is accepted for restricted use within NHSScotland. Indication under review: reduction of intraocular pressure (IOP) in patients with open angle glaucoma and ocular hypertension who are insufficiently responsive to topical beta-blockers or prostaglandin analogues. SMC restriction: to use

2019 Scottish Medicines Consortium

4. Therapeutic efficacy of latanoprost on primary open angle glaucoma: A protocol for a systematic review of randomized controlled trial. (Full text)

Therapeutic efficacy of latanoprost on primary open angle glaucoma: A protocol for a systematic review of randomized controlled trial. Latanoprost is quiet new formulation that is approved for the treatment of primary open angle glaucoma (POAG). However, no updated systematic review has addressed its efficacy for POAG. This systematic review of randomized controlled trials (RCTs) aims to assess its efficacy and safety for the treatment of patients with POAG.This study will search the databases (...) of CENTRAL, EMBASE, MEDILINE, CINAHL, AMED and Chinese databases without language restrictions from their inception to the present. It will only include RCTs of latanoprost for POAG. The quality of the included RCTs will be evaluated by the tool of Cochrane risk of bias. The primary outcomes will be measured by the mean IOP reduction from baseline to the endpoint. The secondary outcomes will be assessed by the mean IOP, adjusted mean IOP reduction at each time point, quality of life, and adverse events

2018 Medicine PubMed abstract

5. Latanoprost

Latanoprost Top results for latanoprost - Trip Database or use your Google+ account Find evidence fast ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4 (...) ) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for latanoprost The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you

2018 Trip Latest and Greatest

6. Netarsudil plus latanoprost (Roclatan) for glaucoma or ocular hypertension

Netarsudil plus latanoprost (Roclatan) for glaucoma or ocular hypertension Netarsudil plus latanoprost (Roclatan) for glaucoma or ocular hypertension | Innovation Observatory toggle menu Menu Search View All Filter by Speciality Filter by Year Filter by Category This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development (...) as these outputs are produced as required for our stakeholders. > > > Netarsudil plus latanoprost (Roclatan) for glaucoma or ocular hypertension Netarsudil plus latanoprost (Roclatan) for glaucoma or ocular hypertension September 2017 Glaucoma describes a group of disorders characterised by sight loss. Glaucoma is generally associated with high pressure in the liquids inside the eye but it can happen when the pressure level is normal. Individuals with consistently high eye pressure are at risk of developing

2017 NIHR Innovation Observatory

7. Monoprost - latanoprost - glaucoma and ocular hypertension

Monoprost - latanoprost - glaucoma and ocular hypertension latanoprost | CADTH.ca Find the information you need latanoprost latanoprost Last Updated: May 17, 2018 Result type: Reports Project Number: SR0541-000 Product Line: Generic Name: latanoprost Brand Name: Monoprost Manufacturer: Laboratoires Théa Indications: glaucoma and ocular hypertension Submission Type: New Project Status: Complete Biosimilar: No Date Recommendation Issued: April 24, 2018 Recommendation Type: Reimburse with clinical

2017 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

8. Benefits of switching from latanoprost to preservative-free tafluprost eye drops: a meta-analysis of two Phase IIIb clinical trials. (Full text)

Benefits of switching from latanoprost to preservative-free tafluprost eye drops: a meta-analysis of two Phase IIIb clinical trials. Glaucoma patients frequently exhibit ocular surface side effects during treatment with prostaglandin eye drops. The present work investigated whether glaucoma patients suffering from signs and symptoms of ocular surface disease while using preserved latanoprost eye drops benefited from switching to preservative-free tafluprost eye drops.The analysis was based (...) on 339 glaucoma patients enrolled in two Phase IIIb trials. The patients were required to have two symptoms, or one sign and one symptom of ocular surface disease at baseline, and at least 6 months preceding treatment with latanoprost eye drops preserved with benzalkonium chloride. All eligible patients were switched from latanoprost to preservative-free tafluprost for a total of 12 weeks. Ocular symptoms and ocular signs were evaluated at baseline and at 2 weeks, 6 weeks, and 12 weeks after

2016 Clinical ophthalmology (Auckland, N.Z.) PubMed abstract

9. Latanoprost (Xalatan): increased reporting of eye irritation since reformulation

Latanoprost (Xalatan): increased reporting of eye irritation since reformulation Latanoprost (Xalatan): increased reporting of eye irritation since reformulation - GOV.UK GOV.UK uses cookies to make the site simpler. or Search Latanoprost (Xalatan): increased reporting of eye irritation since reformulation Advise patients to tell their health professional if they experience severe eye irritation. Published 20 July 2015 From: Therapeutic area: When prescribing or dispensing the Xalatan brand (...) of latanoprost: advise patients to tell their health professional if they experience severe eye irritation review treatment if patients mention severe eye irritation please continue to report suspected side effects to latanoprost or any other medicines on a Xalatan is an eye-drop formulation of latanoprost. It is licensed for the reduction of intraocular pressure in adults and children with ocular hypertension and open angle glaucoma. In 2013, the Xalatan pH was reduced from 6.7 to 6.0 to allow for long-term

2015 MHRA Drug Safety Update

10. Latanoprost for open-angle glaucoma (UKGTS): a randomised, multicentre, placebo-controlled trial. (Full text)

Latanoprost for open-angle glaucoma (UKGTS): a randomised, multicentre, placebo-controlled trial. Treatments for open-angle glaucoma aim to prevent vision loss through lowering of intraocular pressure, but to our knowledge no placebo-controlled trials have assessed visual function preservation, and the observation periods of previous (unmasked) trials have typically been at least 5 years. We assessed vision preservation in patients given latanoprost compared with those given placebo.In (...) this randomised, triple-masked, placebo-controlled trial, we enrolled patients with newly diagnosed open-angle glaucoma at ten UK centres (tertiary referral centres, teaching hospitals, and district general hospitals). Eligible patients were randomly allocated (1:1) with a website-generated randomisation schedule, stratified by centre and with a permuted block design, to receive either latanoprost 0·005% (intervention group) or placebo (control group) eye drops. Drops were administered from identical bottles

2014 Lancet Controlled trial quality: predicted high PubMed abstract

11. Meta-analysis of the Efficacy and Safety of Latanoprost Monotherapy in Patients With Angle-closure Glaucoma. (Abstract)

Meta-analysis of the Efficacy and Safety of Latanoprost Monotherapy in Patients With Angle-closure Glaucoma. To systematically evaluate the safety and efficacy of latanoprost monotherapy for the treatment of patients with angle-closure glaucoma.We searched EMBASE, Medline, Cochrane Library, Chinese Journal Full-text Database (CNKI), Chinese Science and Technology Periodical Database (VIP), and Wang Fang using the search terms "latanoprost" (or its commercial name, Xalatan) and "angle-closure (...) heterogeneity, the random-effects model was applied. With the exception of 2 non-Asian populations from Australia and Peru, all 13 countries included in this study were from Asia. Latanoprost reduced mean IOP by 7.9 mm Hg (32.4%), peak IOP by 7.4 mm Hg (29.8%), and trough IOP by 7.9 mm Hg (32.5%). The most frequent ocular adverse effects were ocular hyperemia, discomfort (including eye irritation, ocular discomfort, foreign body sensation, and itching), and blurred vision with a total incidence rate of 9.4

2014 Journal of glaucoma

12. Fixed combination of latanoprost and timolol vs the individual components for primary open angle glaucoma and ocular hypertension: a systematic review and meta-analysis. (Full text)

Fixed combination of latanoprost and timolol vs the individual components for primary open angle glaucoma and ocular hypertension: a systematic review and meta-analysis. To assess the effects of the fixed combination of 0.005% latanoprost and 0.5% timolol (FCLT) vs their individual components for primary open angle glaucoma (POAG) and ocular hypertension (OHT).After searched PubMed, EMBASE, the Cochrane Library and SCI, all randomized controlled clinical trials (RCTs) and cross-over studies (...) were included. The control groups were the mono therapy or the concomitant therapy of latanoprost and timolol. The outcomes were visual field defect, optic atrophy, mean intraocular pressure (IOP) and IOP fluctuation. The analysis was carried out in RevMan version 5.1 software.The post-intervention mean IOP of FCLT was significantly lower compared to timolol [mean difference (MD) -2.92, 95%CI -3.28 to -2.55, P<0.00001] and latanoprost (MD -1.11, 95%CI -1.51 to -0.72, P<0.00001). The post

2014 International journal of ophthalmology PubMed abstract

13. Latanoprost

Latanoprost USE OF LATANOPROST IN PREGNANCY 0344 892 0909 USE OF LATANOPROST IN PREGNANCY (Date of issue: February 2016 , Version: 2 ) This is a UKTIS monograph for use by health care professionals. For case-specific advice please contact UKTIS on 0344 892 0909. To report an exposure please download and complete a . Please encourage all women to complete an . Summary Latanoprost is a prostaglandin analogue used topically in the treatment of ocular hypertension and open-angle glaucoma. Systemic (...) use of prostaglandins can increase uterine tone, have known abortifacient effects, and may also cause reduced placental perfusion to the fetus, raising concerns regarding their use during pregnancy. However, latanoprost is currently only licensed for ocular administration, therefore a high systemic concentration following use would not be expected at the recommended therapeutic dose of 1.5 micrograms/day. There are no large epidemiological studies on the use of latanoprost during pregnancy

2014 UK Teratology Information Service

14. Meta-analysis of randomized controlled trials comparing latanoprost with other glaucoma medications in chronic angle-closure glaucoma. (Abstract)

Meta-analysis of randomized controlled trials comparing latanoprost with other glaucoma medications in chronic angle-closure glaucoma. To evaluate the efficacy and safety of latanoprost compared with other glaucoma medications in the treatment of chronic angle-closure glaucoma (CACG) and to provide the basis for clinical medication.Major literature databases were searched for randomized controlled trials (RCT) involving latanoprost among patients with CACG. Primary outcome measures were (...) absolute changes in intraocular pressure (IOP) and incidence of ocular adverse events. Statistical analyses included the calculation of standardized mean difference (SMD) and relative risk (RR). The statistical analysis was performed using STATA version 12.0 software.Ten RCT involving 1096 patients were included in this meta-analysis. Analysis showed that latanoprost was not significantly different from other glaucoma medications in reducing IOP (SMD = 0.29, 95% confidence interval [CI] -0.02 to 0.59

2014 European journal of ophthalmology

15. Meta-analysis of randomized controlled trials comparing latanoprost with timolol in the treatment of asian populations with chronic angle-closure glaucoma. (Full text)

Meta-analysis of randomized controlled trials comparing latanoprost with timolol in the treatment of asian populations with chronic angle-closure glaucoma. To evaluate the efficacy and safety of latanoprost compared with timolol in the treatment of Asian patients with chronic angle-closure glaucoma (CACG).Relevant trials were identified through systematic searches of Medline, EMBASE, PubMed, Cochrane Library, Google Scholar and several Chinese databases. The main outcome measures included (...) absolute and relative reduction of intraocular pressure (IOP) at mean, peak and trough from baseline, ocular adverse effects and systemic adverse events.Seven randomized controlled trials with 685 patients were included. In comparison with timolol, latanoprost reduced absolute IOP in CACG patients by more than 2.3 mmHg (95%CI, 1.8∼2.9, P<0.01), 2.4 mmHg (95%CI, 1.9∼2.9, P<0.01) and 2.5 mmHg (95%CI, 1.6∼3.3, P<0.01) at mean, peak and trough, respectively. As for relative IOP, there is 9.0% (95%CI, 6.6

2014 PloS one PubMed abstract

16. Efficacy and tolerability of latanoprost compared with timolol in the treatment of patients with chronic angle-closure glaucoma. (Abstract)

Efficacy and tolerability of latanoprost compared with timolol in the treatment of patients with chronic angle-closure glaucoma. To evaluate the efficacy and tolerability of latanoprost compared with timolol in the treatment of patients with chronic angle-closure glaucoma (CACG).Pertinent publications were identified through systematic searches of PubMed, EMBASE, the Cochrane Controlled Trials Register and the Chinese Biomedicine Database. Randomized controlled trials comparing latanoprost (...) 5.2 software.Five published randomized controlled trials involving 528 patients were included in the present meta-analysis. The IOP reduction (IOPR) was significantly greater in the latanoprost group than in the timolol group at diurnal curve (WMD: 2.22 mmHg [95% CI, 1.65 to 2.79], P < 0.00001), peak (WMD: 2.44 mmHg [0.85 to 4.03], P = 0.003) and trough (WMD: 2.67 mmHg [1.93 to 3.41], P < 0.00001). Timolol caused conjunctival hyperemia in less patients than latanoprost (pooled OR: 2.74 [95% CI

2014 Current medical research and opinion

17. Relative efficacy and safety of preservative-free latanoprost (T2345) for the treatment of open-angle glaucoma and ocular hypertension: an adjusted Indirect comparison meta-analysis of randomized clinical trials. (Full text)

Relative efficacy and safety of preservative-free latanoprost (T2345) for the treatment of open-angle glaucoma and ocular hypertension: an adjusted Indirect comparison meta-analysis of randomized clinical trials. To assess the relative efficacy and tolerability of preservative-free latanoprost (T2345) compared with other prostaglandin analogues (PGA) for the treatment of open-angle glaucoma and ocular hypertension by adjusted indirect comparison meta-analysis.Randomized, controlled trials (...) of hyperemia.Twenty-one studies were included in the meta-analysis. No statistically significant differences in IOP at 3 months were seen between T2345 and travoprost [preserved with benzalkonium chloride (BAK), polyquaternium-1 or sofzia], and other BAK-preserved PGA: bimatoprost 0.03%, bimatoprost 0.01%, or latanoprost. T2345 was statistically significantly superior to BAK-tafluprost (mean difference: 0.47 mm Hg, 95% confidence interval, [-1.52;-0.28]). The risk of hyperemia was statistically significantly

2014 Journal of Glaucoma PubMed abstract

18. Efficacy and Tolerability of the Fixed Combinations Latanoprost/Timolol versus Dorzolamide/Timolol in Patients with Elevated Intraocular Pressure: A Meta-Analysis of Randomized Controlled Trials. (Full text)

Efficacy and Tolerability of the Fixed Combinations Latanoprost/Timolol versus Dorzolamide/Timolol in Patients with Elevated Intraocular Pressure: A Meta-Analysis of Randomized Controlled Trials. To evaluate the efficacy and tolerability of the fixed combination of Latanoprost/Timolol versus Dorzolamide/Timolol in the treatment of patients with elevated intraocular pressure (IOP).A comprehensive literature meta-analysis was performed according to the Cochrane Collaboration methodology (...) to identify randomized clinical trials comparing latanoprost/timolol FC (FCLT) with dorzolamide/timolol (FCDT) in patients with elevated IOP. The efficacy estimates were measured by the weight mean difference (WMD) for the IOP reduction (IOPR) from baseline to end point, including the diurnal mean IOPR, 8 AM IOPR, 12 PM IOPR, and 4 PM IOPR. The tolerability estimates were measured by RR for adverse events. All outcomes were reported with a 95% confidence interval (CI). The data were synthesized by Stata

2013 PloS one PubMed abstract

19. Latanoprost versus timolol as first choice therapy in patients with ocular hypertension

Latanoprost versus timolol as first choice therapy in patients with ocular hypertension Latanoprost versus timolol as first choice therapy in patients with ocular hypertension Latanoprost versus timolol as first choice therapy in patients with ocular hypertension Peeters A, Schouten JS, Severens JL, Hendrikse F, Prins MH, Webers CA Record Status This is an economic evaluation that meets the criteria for inclusion on NHS EED. CRD summary The study examined the cost-effectiveness of first-line (...) treatment with either latanoprost or timolol for the management of ocular hypertension. The authors concluded that treatment starting with latanoprost was not cost-effective compared with treatment starting with timolol because of small differences in health benefits and the high price of latanoprost. The analysis was based on a valid modelling framework. The authors’ conclusions appear robust. Type of economic evaluation Cost-effectiveness analysis Study objective The study examined the cost

2012 NHS Economic Evaluation Database.

20. Treatment persistence and cost-effectiveness of latanoprost/latanoprost-timolol, bimatoprost/bimatoprost-timolol, and travoprost/travoprost-timolol in glaucoma: an analysis based on the United Kingdom general practitioner research database (Full text)

Treatment persistence and cost-effectiveness of latanoprost/latanoprost-timolol, bimatoprost/bimatoprost-timolol, and travoprost/travoprost-timolol in glaucoma: an analysis based on the United Kingdom general practitioner research database Treatment persistence and cost-effectiveness of latanoprost/latanoprost-timolol, bimatoprost/bimatoprost-timolol, and travoprost/travoprost-timolol in glaucoma: an analysis based on the United Kingdom general practitioner research database Treatment (...) persistence and cost-effectiveness of latanoprost/latanoprost-timolol, bimatoprost/bimatoprost-timolol, and travoprost/travoprost-timolol in glaucoma: an analysis based on the United Kingdom general practitioner research database Lafuma A, Salmon JF, Robert J, Berdeaux G Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical

2011 NHS Economic Evaluation Database. PubMed abstract